EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression

Jiuhui Xu, Qianyu Shi, Jingbing Lou, Boyang Wang, Wei Wang, Jianfang Niu, Lei Guo, Chenglong Chen, Yiyang Yu, Yi Huang, Wei Guo, Jianqiang Lan und 3 weitere

Journal for ImmunoTherapy of Cancer · 2023-04 · 11 (4) · e006808

DOI: 10.1136/jitc-2023-006808 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 25.04.2023. Verfasst von Jiuhui Xu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Tumor-Associated Macrophages, Chordoma. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chordoma is an extremely rare, locally aggressive malignant bone tumor originating from undifferentiated embryonic remnants. There are no effective therapeutic strategies for chordoma. Herein, we aimed to explore cellular interactions within the chordoma immune microenvironment and provide new therapeutic targets.

Methods

Spectrum flow cytometry and multiplex immunofluorescence (IF) staining were used to investigate the immune microenvironment of chordoma. Cell Counting Kit-8, Edu, clone formation, Transwell, and healing assays were used to validate tumor functions. Flow cytometry and Transwell assays were used to analyze macrophage phenotype and chemotaxis alterations. Immunohistochemistry, IF, western blot, PCR, and ELISA assays were used to analyze molecular expression. An organoid model and a xenograft mouse model were constructed to investigate the efficacy of maraviroc (MVC).

Results

The chordoma immune microenvironment landscape was characterized, and we observed that chordoma exhibits a typical immune exclusion phenotype. However, macrophages infiltrating the tumor zone were also noted. Through functional assays, we demonstrated that chordoma-secreted CCL5 significantly promoted malignancy progression, macrophage recruitment, and M2 polarization. In turn, M2 macrophages markedly enhanced the proliferation, invasion, and migration viability of chordoma. CCL5 knockdown and MVC (CCL5/CCR5 inhibitor) treatment both significantly inhibited chordoma malignant progression and M2 macrophage polarization. We established chordoma patient-derived organoids, wherein MVC exhibited antitumor effects, especially in patient 4, with robust killing effect. MVC inhibits chordoma growth and lung metastasis in vivo.

Conclusions

Our study implicates that the CCL5–CCR5 axis plays an important role in the malignant progression of chordoma and the regulation of macrophages, and that the CCL5–CCR5 axis is a potential therapeutic target in chordoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor-Associated MacrophagesChordomaHumansAnimalsMiceMacrophagesMaravirocDisease Models, AnimalTumor MicroenvironmentChemokine CCL5

Stichwörter der Autor:innen

Sarcoma

Substanzen

MaravirocCCL5 protein, humanChemokine CCL5

Autor:innen und Institutionen

  • Department of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, China.
  • Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, China.
  • Beijing Jishuitan Hospital, Beijing, Beijing, China.
  • Accurate International Biotechnology Co Ltd, Guangzhou, Hong Kong, China.
  • Department of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, China tangxiaodong@pkuph.edu.cn tumorcenter@163.com.

ORCID-Profile: Xiaodong Tang

Förderung

  • Natural Science Foundation of Beijing Municipality
  • National Natural Science Foundation of China

Zitieren

APA

Xu, J., Shi, Q., Lou, J., Wang, B., Wang, W., Niu, J., Guo, L., Chen, C., Yu, Y., Huang, Y., Guo, W., Lan, J., Zhu, Y., Ren, T., & Tang, X. (2023). Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression. Journal for ImmunoTherapy of Cancer, 11(4), e006808. https://doi.org/10.1136/jitc-2023-006808

Vancouver

Xu J, Shi Q, Lou J, Wang B, Wang W, Niu J, et al. Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression. Journal for ImmunoTherapy of Cancer. 2023;11(4):e006808. doi:10.1136/jitc-2023-006808

BibTeX
@article{Xu2023,
  author = {Xu, Jiuhui and Shi, Qianyu and Lou, Jingbing and Wang, Boyang and Wang, Wei and Niu, Jianfang and Guo, Lei and Chen, Chenglong and Yu, Yiyang and Huang, Yi and Guo, Wei and Lan, Jianqiang and Zhu, Yu and Ren, Tingting and Tang, Xiaodong},
  title = {Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {4},
  pages = {e006808},
  doi = {10.1136/jitc-2023-006808}
}
Kostenlos starten →